Medical - Devices
Compare Stocks
5 / 10Stock Comparison
VREX vs XRAY vs NNOX vs ATEC vs HOLX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Devices
Medical - Instruments & Supplies
VREX vs XRAY vs NNOX vs ATEC vs HOLX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $496M | $2.20B | $115M | $1.17B | $16.97B |
| Revenue (TTM) | $858M | $3.68B | $12M | $595M | $4.13B |
| Net Income (TTM) | $-83M | $-628M | $-56M | $-125M | $544M |
| Gross Margin | 33.6% | 48.9% | -98.8% | 89.6% | 52.8% |
| Operating Margin | -3.7% | 4.1% | -469.7% | -9.6% | 17.5% |
| Forward P/E | 13.9x | 7.7x | — | 27.1x | 17.2x |
| Total Debt | $402M | $2.47B | $7M | $620M | $2.63B |
| Cash & Equiv. | $145M | $326M | $39M | $161M | $1.96B |
VREX vs XRAY vs NNOX vs ATEC vs HOLX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Varex Imaging Corpo… (VREX) | 100 | 70.9 | -29.1% |
| DENTSPLY SIRONA Inc. (XRAY) | 100 | 20.9 | -79.1% |
| Nano-X Imaging Ltd. (NNOX) | 100 | 3.9 | -96.1% |
| Alphatec Holdings, … (ATEC) | 100 | 53.4 | -46.6% |
| Hologic, Inc. (HOLX) | 100 | 103.8 | +3.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VREX vs XRAY vs NNOX vs ATEC vs HOLX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VREX ranks third and is worth considering specifically for momentum.
- +44.8% vs NNOX's -64.4%
XRAY is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (7.7x vs 27.1x)
- 5.9% yield; 23-year raise streak; the other 4 pay no meaningful dividend
NNOX is the clearest fit if your priority is growth exposure.
- Rev growth 13.9%, EPS growth 15.7%, 3Y rev CAGR 105.3%
ATEC is the clearest fit if your priority is long-term compounding.
- 225.4% 10Y total return vs HOLX's 124.3%
- 25.0% revenue growth vs XRAY's -3.0%
HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
- 13.2% margin vs NNOX's -452.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 25.0% revenue growth vs XRAY's -3.0% | |
| Value | Lower P/E (7.7x vs 27.1x) | |
| Quality / Margins | 13.2% margin vs NNOX's -452.8% | |
| Stability / Safety | Beta 0.41 vs VREX's 1.87, lower leverage | |
| Dividends | 5.9% yield; 23-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +44.8% vs NNOX's -64.4% | |
| Efficiency (ROA) | 6.1% ROA vs NNOX's -31.6%, ROIC 9.4% vs -27.9% |
VREX vs XRAY vs NNOX vs ATEC vs HOLX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
VREX vs XRAY vs NNOX vs ATEC vs HOLX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HOLX leads in 4 of 6 categories
XRAY leads 1 • VREX leads 0 • NNOX leads 0 • ATEC leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
HOLX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HOLX is the larger business by revenue, generating $4.1B annually — 335.4x NNOX's $12M. HOLX is the more profitable business, keeping 13.2% of every revenue dollar as net income compared to NNOX's -4.5%. On growth, NNOX holds the edge at +13.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $858M | $3.7B | $12M | $595M | $4.1B |
| EBITDAEarnings before interest/tax | -$18M | $424M | -$46M | $4M | $974M |
| Net IncomeAfter-tax profit | -$83M | -$628M | -$56M | -$125M | $544M |
| Free Cash FlowCash after capex | -$31M | $104M | -$47M | $7M | $1000M |
| Gross MarginGross profit ÷ Revenue | +33.6% | +48.9% | -98.8% | +89.6% | +52.8% |
| Operating MarginEBIT ÷ Revenue | -3.7% | +4.1% | -4.7% | -9.6% | +17.5% |
| Net MarginNet income ÷ Revenue | -9.6% | -17.1% | -4.5% | -21.1% | +13.2% |
| FCF MarginFCF ÷ Revenue | -3.6% | +2.8% | -3.8% | +1.2% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.5% | +0.1% | +13.7% | -100.0% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.5% | -150.0% | +8.7% | +37.1% | -9.2% |
Valuation Metrics
XRAY leads this category, winning 2 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, XRAY's 7.2x EV/EBITDA is more attractive than ATEC's 3752.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $496M | $2.2B | $115M | $1.2B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $753M | $4.3B | $83M | $1.6B | $17.6B |
| Trailing P/EPrice ÷ TTM EPS | -6.96x | -3.65x | -1.93x | -8.07x | 30.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.92x | 7.68x | — | 27.09x | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.18x | — | 3752.09x | 17.39x |
| Price / SalesMarket cap ÷ Revenue | 0.59x | 0.60x | 10.20x | 1.54x | 4.14x |
| Price / BookPrice ÷ Book value/share | 1.01x | 1.63x | 0.55x | 32.28x | 3.43x |
| Price / FCFMarket cap ÷ FCF | 26.38x | 21.11x | — | 422.56x | 18.44x |
Profitability & Efficiency
HOLX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
HOLX delivers a 11.0% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-4 for ATEC. NNOX carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATEC's 17.21x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs NNOX's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.1% | -41.2% | -35.5% | -4.4% | +11.0% |
| ROA (TTM)Return on assets | -7.6% | -11.2% | -31.6% | -15.8% | +6.1% |
| ROICReturn on invested capital | -2.6% | +5.1% | -27.9% | -12.6% | +9.4% |
| ROCEReturn on capital employed | -2.9% | +6.1% | -28.4% | -13.7% | +8.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 4 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.83x | 1.84x | 0.04x | 17.21x | 0.52x |
| Net DebtTotal debt minus cash | $257M | $2.1B | -$32M | $459M | $667M |
| Cash & Equiv.Liquid assets | $145M | $326M | $39M | $161M | $2.0B |
| Total DebtShort + long-term debt | $402M | $2.5B | $7M | $620M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | -4.94x | -5.12x | -379.29x | -3.29x | 8.00x |
Total Returns (Dividends Reinvested)
HOLX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HOLX five years ago would be worth $11,582 today (with dividends reinvested), compared to $605 for NNOX. Over the past 12 months, VREX leads with a +44.8% total return vs NNOX's -64.4%. The 3-year compound annual growth rate (CAGR) favors HOLX at -2.9% vs NNOX's -52.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.5% | -2.8% | -37.8% | -62.7% | +1.9% |
| 1-Year ReturnPast 12 months | +44.8% | -16.4% | -64.4% | -37.8% | +37.1% |
| 3-Year ReturnCumulative with dividends | -46.3% | -69.4% | -89.2% | -47.8% | -8.5% |
| 5-Year ReturnCumulative with dividends | -51.8% | -80.1% | -93.9% | -48.7% | +15.8% |
| 10-Year ReturnCumulative with dividends | -58.0% | -74.5% | -96.1% | +225.4% | +124.3% |
| CAGR (3Y)Annualised 3-year return | -18.7% | -32.6% | -52.4% | -19.5% | -2.9% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than VREX's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs NNOX's 30.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 1.78x | 1.86x | 1.13x | 0.41x |
| 52-Week HighHighest price in past year | $14.56 | $17.18 | $5.86 | $23.29 | $76.04 |
| 52-Week LowLowest price in past year | $6.76 | $9.85 | $1.66 | $6.85 | $52.81 |
| % of 52W HighCurrent price vs 52-week peak | +81.2% | +63.8% | +30.0% | +33.3% | +100.0% |
| RSI (14)Momentum oscillator 0–100 | 56.6 | 39.2 | 38.5 | 26.8 | 69.1 |
| Avg Volume (50D)Average daily shares traded | 261K | 4.2M | 1.4M | 3.0M | 10.0M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: VREX as "Buy", XRAY as "Hold", NNOX as "Buy", ATEC as "Buy", HOLX as "Hold". Consensus price targets imply 922.7% upside for NNOX (target: $18) vs 3.9% for HOLX (target: $79). XRAY is the only dividend payer here at 5.86% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $14.50 | $13.40 | $18.00 | $25.00 | $79.00 |
| # AnalystsCovering analysts | 6 | 31 | 5 | 16 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +5.9% | — | — | — |
| Dividend StreakConsecutive years of raises | — | 23 | — | — | — |
| Dividend / ShareAnnual DPS | — | $0.64 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | +4.4% |
HOLX leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XRAY leads in 1 (Valuation Metrics).
VREX vs XRAY vs NNOX vs ATEC vs HOLX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VREX or XRAY or NNOX or ATEC or HOLX a better buy right now?
For growth investors, Alphatec Holdings, Inc.
(ATEC) is the stronger pick with 25. 0% revenue growth year-over-year, versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Varex Imaging Corporation (VREX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VREX or XRAY or NNOX or ATEC or HOLX?
On forward P/E, DENTSPLY SIRONA Inc.
is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — VREX or XRAY or NNOX or ATEC or HOLX?
Over the past 5 years, Hologic, Inc.
(HOLX) delivered a total return of +15. 8%, compared to -93. 9% for Nano-X Imaging Ltd. (NNOX). Over 10 years, the gap is even starker: ATEC returned +225. 4% versus NNOX's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VREX or XRAY or NNOX or ATEC or HOLX?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus Varex Imaging Corporation's 1. 87β — meaning VREX is approximately 356% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Nano-X Imaging Ltd. (NNOX) carries a lower debt/equity ratio of 4% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VREX or XRAY or NNOX or ATEC or HOLX?
By revenue growth (latest reported year), Alphatec Holdings, Inc.
(ATEC) is pulling ahead at 25. 0% versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). On earnings-per-share growth, the picture is similar: DENTSPLY SIRONA Inc. grew EPS 33. 0% year-over-year, compared to -45. 3% for Varex Imaging Corporation. Over a 3-year CAGR, NNOX leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VREX or XRAY or NNOX or ATEC or HOLX?
Hologic, Inc.
(HOLX) is the more profitable company, earning 13. 8% net margin versus -474. 3% for Nano-X Imaging Ltd. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -502. 9% for NNOX. At the gross margin level — before operating expenses — ATEC leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VREX or XRAY or NNOX or ATEC or HOLX more undervalued right now?
On forward earnings alone, DENTSPLY SIRONA Inc.
(XRAY) trades at 7. 7x forward P/E versus 27. 1x for Alphatec Holdings, Inc. — 19. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NNOX: 922. 7% to $18. 00.
08Which pays a better dividend — VREX or XRAY or NNOX or ATEC or HOLX?
In this comparison, XRAY (5.
9% yield) pays a dividend. VREX, NNOX, ATEC, HOLX do not pay a meaningful dividend and should not be held primarily for income.
09Is VREX or XRAY or NNOX or ATEC or HOLX better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Nano-X Imaging Ltd. (NNOX) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NNOX: -96. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VREX and XRAY and NNOX and ATEC and HOLX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VREX is a small-cap quality compounder stock; XRAY is a small-cap income-oriented stock; NNOX is a small-cap quality compounder stock; ATEC is a small-cap high-growth stock; HOLX is a mid-cap quality compounder stock. XRAY pays a dividend while VREX, NNOX, ATEC, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.